北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第三临床医学院  > 血液内科  > 期刊论文
学科主题: 临床医学
题名:
A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma
作者: Geng, Chuanying1; Hou, Jian2; Zhao, Yaozhong3,4,5; Ke, Xiaoyan6; Wang, Zhao7; Qiu, Lugui3,4,5; Xi, Hao2; Wang, Fuxu8; Wei, Na7; Liu, Yan6; Yang, Shifang9; Wei, Peng9; Zheng, Xiangjun9; Huang, Zhongxia1; Zhu, Bing9; Chen, Wen-Ming1
刊名: AMERICAN JOURNAL OF HEMATOLOGY
发表日期: 2014-11-01
DOI: 10.1002/ajh.23822
卷: 89, 期:11, 页:1037-1042
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Hematology
研究领域[WOS]: Hematology
关键词[WOS]: APOPTOSIS-INDUCING LIGAND ; APO2L/TRAIL ; CELLS ; LENALIDOMIDE ; CASPASE-8 ; EFFICACY ; THERAPY ; CANCER ; SAFETY ; MEMBER
英文摘要:

Circularly permuted TRAIL (CPT), a recombinant mutant of human Apo2L/TRAIL, is a novel antitumor candidate for multiple myeloma (MM) and other hematologic malignancies. In this phase II study, the safety and efficacy of CPT plus thalidomide was investigated in thalidomide-resistant MM patients. A total of 43 patients were recruited into three CPT plus thalidomide cohorts based on CPT dosage in sequence: 5 mg/kg (n=11), 8 mg/kg (n=17), and 10 mg/kg (n=15). CPT was administered via intravenous infusion on days 1-5, and thalidomide was given orally at 100 mg once daily in each 21-day cycle. The overall response rate (ORR) of 41 efficacy-evaluable patients was 22.0% (2 complete response, 3 near complete response, and 4 partial response). No significant difference in the ORR was observed among the three dose cohorts; however, the ORR tended to be higher with the higher-dose regimen. Median progression-free survival and median duration of response were 6.6 months and 6.1 months, respectively. The most common treatment-related adverse events (TRAEs) were neutropenia (46.5%), leukopenia (41.9%), fever (37.2%), elevated AST (32.6%), and elevated ALT (20.9%). TRAEs of Grade 3-4 were mainly neutropenia (18.6%), anemia (9.3%), elevated AST (7.0%), and leukopenia (4.7%). No significant differences were found in the incidence and severity of TRAEs among the three cohorts. In conclusion, CPT plus thalidomide was well tolerated with no occurrence of dose-limiting toxicities and demonstrated promising antitumor activity in RRMM patients. CPT at 10 mg/kg for 5 days in combination with thalidomide and dexamethason will be studied in the next clinical trial. Am. J. Hematol. 89:1037-1042, 2014. (c) 2014 Wiley Periodicals, Inc.

语种: 英语
项目资助者: Beijing Sunbio Biotechnology Co., Ltd.
WOS记录号: WOS:000344010100009
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/64995
Appears in Collections:北京大学第三临床医学院_血液内科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Capital Med Univ, Beijing Chao Yang Hosp, Dept Hematol, Beijing 100020, Peoples R China
2.Second Mil Med Univ, Chang Zheng Hosp, Dept Hematol, Shanghai, Peoples R China
3.CAMS, Inst Hematol, Dept Lymphoma Ctr, Tianjin, Peoples R China
4.CAMS, Blood Dis Hosp, Tianjin, Peoples R China
5.PUMC, Tianjin, Peoples R China
6.Hebei Med Univ, Hosp 2, Dept Hematol, Hebei, Peoples R China
7.Beijing Sunbio Biotechnol Co Ltd, Beijing, Peoples R China
8.Peking Univ, Dept Hematol, Hosp 3, Beijing 100871, Peoples R China
9.Capital Med Univ, Beijing Friendship Hosp, Dept Hematol, Beijing, Peoples R China

Recommended Citation:
Geng, Chuanying,Hou, Jian,Zhao, Yaozhong,et al. A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma[J]. AMERICAN JOURNAL OF HEMATOLOGY,2014,89(11):1037-1042.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Geng, Chuanying]'s Articles
[Hou, Jian]'s Articles
[Zhao, Yaozhong]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Geng, Chuanying]‘s Articles
[Hou, Jian]‘s Articles
[Zhao, Yaozhong]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace